Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 17 Breast Neoplasms 10 Carcinoma, Non-Small-Cell Lung 9 Neoplasm Metastasis 6 Prostatic Neoplasms 5 Melanoma 5 Lung Neoplasms 5 Solid Tumor 3 Pain, Postoperative 3 Lymphoma, Non-Hodgkin 3 Lymphoma 3 Leukemia, Myeloid, Acute 3 Gastrointestinal Stromal Tumors 3 Colorectal Neoplasms 3 Anxiety Disorders 3 Recurrence 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pancreatic Neoplasms 2 Pain 2 Glioma 2 Colonic Neoplasms 2 Choledocholithiasis 2 Choledochal Cyst 2 Carcinoma 2 Advanced Solid Tumor 2 Advanced Malignancies 2 cMET-dysregulated Advanced Solid Tumors 1 Urothelial Cancer 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1

Interventions

enzalutamide 7 Prednisone 7 cabazitaxel 6 Radiosurgery 6 Docetaxel 5 Androgen Antagonists 4 Abiraterone Acetate 4 XRP6258 2 Standard of Care 2 talazoparib 1 sipuleucel-T 1 rucaparib 1 pembrolizumab 1 olaparib 1 gallium 68 PSMA-11 1 fludrocortisone acetate 1 darolutamide 1 apalutamide 1 Zuclomiphene 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Prednisolone 1 Positron Emission Tomography Computed Tomography 1 Pluvicto 1 Midazolam 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 LY3023414 1 Injections 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × Midazolam × Clear all

NCT03436485 2025-07-22

CYPIDES

Orion Corporation, Orion Pharma

Phase 1/2 Active not recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡